News & Updates
Filter by Specialty:
Erenumab works well in chronic migraine patients across Asia
Erenumab proves to be effective at lowering the number of monthly migraine days in Asian patients with chronic migraine while having a favourable safety profile, according to the results of DRAGON study.
Erenumab works well in chronic migraine patients across Asia
06 Dec 2022
Weekly somapacitan on par with daily growth hormone in children
Weekly somapacitan is noninferior to daily growth hormone (GH) in terms of height velocity (HV), with comparable safety and mean insulin-like growth factor-1 standard deviation score (IGF-1 SDS) levels in treatment-naïve children with growth hormone deficiency (GHD), a study has shown.
Weekly somapacitan on par with daily growth hormone in children
06 Dec 2022
Itraconazole effective for ringworm of the body but requires longer treatment
Itraconazole appears to be effective in the treatment of patients with tinea corporis/cruris (TCC) or ringworm of the body, as shown in a study. However, the treatment duration needs to be longer and, even with successful treatment, many patients experience relapse.
Itraconazole effective for ringworm of the body but requires longer treatment
06 Dec 2022
Dose reduction needed in HFrEF patients on sacubitril-valsartan
Some patients with heart failure with reduced ejection fraction (HFrEF) need a loop diuretic dose reduction within 2‒3 months following initiation of sacubitril-valsartan, suggests a study.
Dose reduction needed in HFrEF patients on sacubitril-valsartan
05 Dec 2022
Pharmacist-led smoking cessation program prompts quit attempts, IBD medication use
A smoking cessation program led by a pharmacist in a specialty medical home is feasible and may even lead to successful quit attempts and improved use of inflammatory bowel disease (IBD) medications, suggest the results of a study.
Pharmacist-led smoking cessation program prompts quit attempts, IBD medication use
04 Dec 2022
Post-PCI bivalirudin infusion reduces death, bleeding vs heparin
Patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) have a reduced risk of all-cause death or BARC* type 3–5 bleeding when they receive a bolus plus post-PCI high-dose infusion of bivalirudin compared with heparin monotherapy, results of the BRIGHT**-4 trial showed.